ProCE Banner Activity

Managing Advanced ALK-Positive Non-Small-Cell Lung Cancer: Considerations for Community Practitioners

PDF

This short downloadable PDF summarizes key recommendations and data surrounding testing for ALK rearrangements and treatment considerations for advanced ALK-positive NSCLC.

Released: March 27, 2025

Expiration: March 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Disclosure

Primary Author

Todd M. Bauer, MD: consultant/advisor/speaker: Bayer, FMI, Pfizer, Tempus.

Christine Bestvina, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Genentech, Gilead, Guardant, Johnson & Johnson, Mirati, Novocure, Pfizer, Sanofi, Tempus, Turning Point Therapeutics; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb; other financial or material support: AstraZeneca, Bristol Myers Squibb, Guardant, Johnson & Johnson.

Jessica J. Lin, MD: consultant/advisor/speaker: AnHeart Therapeutics, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, C4 Therapeutics, Claim Therapeutics, Daiichi Sankyo, Elevation Oncology, Ellipses, Genentech, Gilead, Janssen, Lilly, Merus, Mirtati Therapeutics, Novartis, Nuvation Bio, Nuvalent, Pfizer, Regeneron, Roche, Takeda, Turing Point Therapeutics, Yuhan; researcher (paid to institution): Bayer, Elevation Oncology, Hengrui Therapeutics, Linnaeus Therapeutics, Neon Therapeutics, Novartis, Nuvalent, Roche, Relay Therapeutics, Turning Point Therapeutics; other (travel support): Bristol Myers Squibb, Merus, Pfizer, Takeda.

Alexander Craig Mackinnon, Jr., MD, PhD, MSHA, has no relevant financial relationships to disclose.

Beth Sandy, MSN, CRNP, FAPO: consultant/advisor/speaker: Amgen, AstraZeneca, Jazz, Lilly, Merck, Pfizer, Takeda.